(Q35808985)

10 August 2017

1 reference

title

Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature (English)

1 reference

10 August 2017

0 references

1 reference

1 reference

Colin Brewer

1

1 reference

PubMed ID

15203443

10 August 2017

Voi Shim Wong

series ordinal

2

1 reference

10 August 2017

1 March 2004

1 reference

10 August 2017

1 reference

10 August 2017

9

1 reference

10 August 2017

1

1 reference

10 August 2017

81-87

1 reference

Naltrexone pharmacotherapy for opioid dependent federal probationers

10 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Naltrexone: lack of effect on hepatic enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Lack of hepatotoxicity with naltrexone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

An open naltrexone treatment study in pathological gambling disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Clonidine and opiate receptor antagonists in the treatment of heroin addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

High-dose naltrexone therapy and dietary counseling for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Naltrexone and self-injurious behavior: a retrospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

Preventing disulfiram hepatitis in alcohol abusers: inappropriate guidelines and the significance of nickel allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13556210410001674130

10.1080/13556210410001674130

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15203443